PolyPid ( (PYPD) ) has shared an update.
PolyPid Ltd. announced the appointment of Yitzchak Jacobovitz to its Board and provided a corporate update alongside its Q4 2024 financial results. In February 2025, PolyPid reported that the Data Safety Monitoring Board recommended continuing its SHIELD II Phase 3 trial for D-PLEX100 to 800 patients, with enrollment expected by March 2025 and results in Q2 2025. This trial is significant for potential NDA submission and commercialization plans. The company also completed a private placement of up to $41 million, extending its cash runway beyond potential NDA approval, and engaged in a collaboration with ImmunoGenesis for novel drug formulations.
More about PolyPid
PolyPid Ltd. is a late-stage biopharmaceutical company focused on improving surgical outcomes. The company is primarily involved in developing D-PLEX100, a product designed to prevent surgical site infections by providing controlled antibacterial activity at the surgical site.
YTD Price Performance: -5.41%
Average Trading Volume: 32,360
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $20.89M
For an in-depth examination of PYPD stock, go to TipRanks’ Stock Analysis page.